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It was with great interest that we read the article by Gumbo andcolleagues titled “Redefining Multidrug-Resistant Tuberculosis
Based on Clinical Response to Combination Therapy” (1). The
authors performed a classification and regression tree (CART)
analysis showing that MIC cutoff values above which therapy fail-
ure was observed are significantly lower than current breakpoints
for isoniazid (INH) and rifampin (RIF). The consequence of the
finding might be that the rate of multidrug-resistant tuberculosis
(MDR TB) is much higher than previously assumed (1).
The impact to revise the definition of MDR TB based on these
new critical concentrations will not only be statistical. Many pa-
tients will receive a second-line treatment regimen for at least 20
months that will be accompanied by a budget impact based on
direct and indirect medical costs. The clinical outcome for these
“new” MDR TB patients who will be treated with a second-line
treatment regimen of drugs with unclear efficacy and more toxic-
ity (2) needs to be established.
As the authors point out correctly, the identification of break-
points should be a pharmacokinetics-pharmacodynamics (PK/PD)-
derived calculation. The CART analysis showed cutoff MIC values
lower than the current breakpoint MICs. The authors choose to
adopt these values to distinguish between patients that would show a
favorable result on first-line treatment and those who would likely fail
on treatment. Alternatively, the authors could also have chosen to
increase the doses of INH and RIF. This would have resulted in the
same PK/PD indices and would reduce the potential increase in the
number of patients labeled as MDR TB, thereby avoiding the inevi-
table consequence of starting a second-line treatment regimen. In-
creasing the doses of INH and RIF can be advocated based on in vitro
and in vivo infection models showing that higher concentrations re-
sult in better outcome (3, 4). For RIF, it is already known that the
current dose of 600 mg once daily is at the low end of the concentra-
tion-effect curve (5). Higher doses of RIF have even been evaluated in
a randomized controlled trial to potentially shorten TB treatment (6);
high doses of INH have been evaluated in the Bangladesh regimen
(2). Both drugs appeared to be well tolerated. So instead of reducing
the denominator of the PK/PD equation, we advocate increasing the
numerator, likely resulting in the same clinical cure rate, thereby
avoiding the increase of MDR TB and subsequent prolonged and
toxic treatment.
We realize that our proposed strategy will likely also have a
major impact on the current first-line treatment. A randomized
study would ultimately be needed to compare clinical outcomes
between standard treatment and treatment with high-dose INH
and RIF. The publication of Gumbo and coworkers once again
showed that new dosing strategies with currently available drugs
are urgently needed to turn the tide of the MDR TB epidemic. It
becomes clearer every day that drug susceptibility was and is im-
portant to be able to select an appropriate MDR TB treatment
regimen (7) and in addition tailor treatment further by optimizing
drug exposure in patients (8).
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